Merck's Oral PCSK9 Inhibitor Enlicitide Significantly Reduces LDL Cholesterol in Phase 3 Trials on June 09, 2025 Administration of prophylactic statin cholesterol CORALreef CORALreef AddOn enlicitide HeFH Hypercholesterolemia, Familial Hyperlipidemia LDL-C Merck oral therapy PCSK9 inhibitor +